Overview

Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma

Status:
Completed
Trial end date:
2020-02-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine tolerability, safety, and pharmacokinetics of YS110 intravenous administration in patients with malignant pleural mesothelioma and to preliminarily examine the anti-tumor effect of YS110.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.